- Home
- ATS vs NAMS Comparison
ATS vs NAMS Comparison
Compare ATS & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATS
- NAMS
- Stock Information
- Founded
- ATS 1978
- NAMS 2019
- Country
- ATS Canada
- NAMS Netherlands
- Employees
- ATS N/A
- NAMS N/A
- Industry
- ATS
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- ATS
- NAMS Health Care
- Exchange
- ATS Nasdaq
- NAMS Nasdaq
- Market Cap
- ATS 3.0B
- NAMS 2.9B
- IPO Year
- ATS 2023
- NAMS N/A
- Fundamental
- Price
- ATS $27.70
- NAMS $25.07
- Analyst Decision
- ATS
- NAMS Strong Buy
- Analyst Count
- ATS 0
- NAMS 9
- Target Price
- ATS N/A
- NAMS $41.00
- AVG Volume (30 Days)
- ATS 142.1K
- NAMS 843.1K
- Earning Date
- ATS 08-07-2025
- NAMS 08-06-2025
- Dividend Yield
- ATS N/A
- NAMS N/A
- EPS Growth
- ATS N/A
- NAMS N/A
- EPS
- ATS N/A
- NAMS N/A
- Revenue
- ATS $1,886,061,785.00
- NAMS $64,006,000.00
- Revenue This Year
- ATS $17.63
- NAMS N/A
- Revenue Next Year
- ATS $8.22
- NAMS $73.09
- P/E Ratio
- ATS N/A
- NAMS N/A
- Revenue Growth
- ATS N/A
- NAMS 762.15
- 52 Week Low
- ATS $20.90
- NAMS $14.06
- 52 Week High
- ATS $33.13
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- ATS 35.17
- NAMS 61.96
- Support Level
- ATS $28.02
- NAMS $24.73
- Resistance Level
- ATS $29.10
- NAMS $25.80
- Average True Range (ATR)
- ATS 0.85
- NAMS 1.33
- MACD
- ATS -0.30
- NAMS 0.17
- Stochastic Oscillator
- ATS 0.76
- NAMS 83.46
About ATS ATS Corporation
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.